30 rows
0.5 mg/kg via IV
Reported in 30 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Ketamine clinical studies for Depressive Disorders include 118 structured dose rows across 79 linked trials. Common source-reported dose patterns include 0.5 mg/kg, 0.5-0.75 mg/kg, 0.25 mg/kg. Interpret these as descriptive trial protocols, not treatment recommendations.
This page summarizes source-structured dosing used in linked human clinical studies. It preserves the source-reported unit, route, frequency, and regimen notes where available.
Patterns group structured dose rows with the same reported dose, route, and regimen type. They preserve source units and do not imply clinical equivalence.
Reported in 30 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 22 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 8 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 4 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 3 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Each row comes from a linked clinical trial intervention. Rows with missing or reviewed-incomplete dosing stay visible instead of being filled by inference.
| Study | Arm | Dose | Route and regimen | Source status |
|---|---|---|---|---|
A Double-Blind Randomized Controlled Trial Using a Low Dose of Ketamine vs Active Placebo in Treating Severe Depression and Suicide | Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose Low-dose IV infusion over 40 minutes | Not reviewed existing-data | a-randomized-double-blind-midazolam-controlled-trial-of-low-dose-ketamine-infusi |
A longitudinal open-label, dose-ranging clinical trial to evaluate the effectiveness of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist, in patients who are experiencing chronic suicidal ideation |
Reported in 3 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Other
Oral ketamine Ketamine |
| 0.5-3 mg/kg |
Oral Individualised; 1–4 weekly (first interval 2 weeks) Oral liquid ketamine 0.5–3.0 mg/kg administered by psychiatrist or nurse; dose chosen per participant tolerability from parent OKTOS study; OKTOS-E: 4–11 doses; OKTOS-M: 7–26 doses. |
Not reviewed existing-data | spectral-changes-of-eeg-following-a-6-week-low-dose-oral-ketamine-treatment-in-a |
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders | Ketamine (IV, nasal, oral) Ketamine | 0.5 mg/kg | IV twice weekly | 8 doses Slow IV infusion 0.5 mg/kg over 40 minutes, twice weekly for 4 weeks. | Not reviewed existing-data | central-nervous-system-related-safety-and-tolerability-of-add-on-ketamine-to-ant |
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders | Ketamine (IV, nasal, oral) Ketamine | 2-2.5 mg/kg | Oral twice weekly | 8 doses Oral solution 2.0–2.5 mg/kg, twice weekly for 4 weeks. | Not reviewed existing-data | central-nervous-system-related-safety-and-tolerability-of-add-on-ketamine-to-ant |
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders | Ketamine (IV, nasal, oral) Ketamine | Not reported | Other twice weekly | 8 doses Intranasal ketamine spray, twice weekly for 4 weeks (dose not specified). | Not reviewed central-nervous-system-related-safety-and-tolerability-of-add-on-ketamine-to-ant |
A Phase 2a Proof-of-Concept Study of R-107 (Extended-Release Ketamine Tablets) for the Treatment of Refractory Major Depressive Disorder (BEDROC) | R-107 120mg Ketamine | 120 mg | Oral | multi-dose twice weekly Extended-release tablets (R-107) | Not reviewed existing-data | randomized-placebo-controlled-phase-2-study-of-extended-release-ketamine-tablets |
A Phase 2a Proof-of-Concept Study of R-107 (Extended-Release Ketamine Tablets) for the Treatment of Refractory Major Depressive Disorder (BEDROC) | R-107 180mg Ketamine | 180 mg | Oral | multi-dose twice weekly Extended-release tablets (R-107) | Not reviewed existing-data | randomized-placebo-controlled-phase-2-study-of-extended-release-ketamine-tablets |
A Phase 2a Proof-of-Concept Study of R-107 (Extended-Release Ketamine Tablets) for the Treatment of Refractory Major Depressive Disorder (BEDROC) | R-107 30mg Ketamine | 30 mg | Oral | multi-dose twice weekly Extended-release tablets (R-107) | Not reviewed existing-data | randomized-placebo-controlled-phase-2-study-of-extended-release-ketamine-tablets |
A Phase 2a Proof-of-Concept Study of R-107 (Extended-Release Ketamine Tablets) for the Treatment of Refractory Major Depressive Disorder (BEDROC) | R-107 60mg Ketamine | 60 mg | Oral | multi-dose twice weekly Extended-release tablets (R-107) | Not reviewed existing-data | randomized-placebo-controlled-phase-2-study-of-extended-release-ketamine-tablets |
A randomised, double blind, active placebo-controlled crossover trial to evaluate the short term efficacy of an N-Methyl-D-Aspartate antagonist for patients with treatment resistant depression | Ketamine Ketamine | 0.25 mg/kg | IV | fixed single dose | 1 dose IV bolus 0.25 mg/kg then infusion 0.25 mg/kg/hr for 45 minutes. | Not reviewed existing-data | ketamine-improves-short-term-plasticity-in-depression-by-enhancing-sensitivity-t |
A Study of Ketamine in Patients With Treatment-resistant Depression | Ketamine 2x/week Ketamine | 0.5 mg/kg | IV two times weekly | 8 doses IV ketamine 0.50 mg/kg, two times weekly for 4 weeks | Not reviewed existing-data | a-double-blind-randomized-placebo-controlled-dose-frequency-study-of-intravenous |
A Study of Ketamine in Patients With Treatment-resistant Depression | Ketamine 3x/week Ketamine | 0.5 mg/kg | IV three times weekly | 12 doses IV ketamine 0.50 mg/kg, three times weekly for 4 weeks | Not reviewed existing-data | a-double-blind-randomized-placebo-controlled-dose-frequency-study-of-intravenous |
An exploratory study of antidepressant treatment using ketamine for treatment-resistant depression | Repeated ketamine infusions Ketamine | 0.5 mg/kg | IV | multi-dose Thrice weekly for 2 weeks | 6 doses Each infusion delivered over 40 minutes. Assessments at baseline and day 13 (after sixth infusion). | Not reviewed existing-data | rapid-and-longer-term-antidepressant-effects-of-repeated-dose-intravenous-ketami |
An open-label clinical trial of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist, with weekly dosing over six weeks, in 25-50 patients who are experiencing chronic suicidal ideation. | Oral ketamine Ketamine | 0.5-3 mg/kg | Oral weekly | 6 doses Start 0.5 mg/kg and titrate 0.1–0.5 mg/kg weekly to 3.0 mg/kg per psychiatrist; supervised administration with ~1 h monitoring post-dose. | Not reviewed existing-data | low-dose-oral-ketamine-treatment-in-chronic-suicidality-an-open-label-pilot-stud |
Antidepressant Effects of Ketamine in Depressed Patients: A Randomized Double-Blind Placebo-Controlled Crossover Pilot | Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose Infused over 40 min | Not reviewed existing-data | antidepressant-effects-of-ketamine-in-depressed-patients |
Ascending-Dose Subcutaneous Ketamine for Treatment-Refractory Anxiety Disorders: Dose-Finding Study (Glue 2017, University of Otago, ANZCTR) | Ketamine 0.25mg/kg Ketamine | 0.25 mg/kg | Subcutaneous | titrated single dose | 1 dose Administered at 1-week intervals in an ascending dose design | Not reviewed existing-data | ketamine-effects-on-eeg-during-therapy-of-treatment-resistant-generalized-anxiet |
Ascending-Dose Subcutaneous Ketamine for Treatment-Refractory Anxiety Disorders: Dose-Finding Study (Glue 2017, University of Otago, ANZCTR) | Ketamine 0.5mg/kg Ketamine | 0.5 mg/kg | Subcutaneous | titrated single dose | 1 dose Administered at 1-week intervals in an ascending dose design | Not reviewed existing-data | ketamine-effects-on-eeg-during-therapy-of-treatment-resistant-generalized-anxiet |
Ascending-Dose Subcutaneous Ketamine for Treatment-Refractory Anxiety Disorders: Dose-Finding Study (Glue 2017, University of Otago, ANZCTR) | Ketamine 1mg/kg Ketamine | 1 mg/kg | Subcutaneous | titrated single dose | 1 dose Administered at 1-week intervals in an ascending dose design | Not reviewed existing-data | ketamine-effects-on-eeg-during-therapy-of-treatment-resistant-generalized-anxiet |
Biomarkers of Fast Acting Therapies in Major Depression | Ketamine Ketamine | 0.5 mg/kg | IV 2-3 times/week | 4 doses Diluted in 60 mL saline and given as a slow IV infusion over 40 minutes; additional doses given if no remission up to 4 | Not reviewed existing-data | neurocognitive-effects-of-subanesthetic-serial-ketamine-infusions-in-treatment-r |
CAP-Ketamine for Antidepressant Resistant PTSD | Low Dose Ketamine | 0.2 mg/kg | IV | multi-dose twice weekly | 8 doses 8 infusions total | Not reviewed existing-data | dose-related-effects-of-ketamine-for-antidepressant-resistant-symptoms-of-posttr |
CAP-Ketamine for Antidepressant Resistant PTSD | Standard Dose Ketamine | 0.5 mg/kg | IV | multi-dose twice weekly | 8 doses 8 infusions total | Not reviewed existing-data | dose-related-effects-of-ketamine-for-antidepressant-resistant-symptoms-of-posttr |
Chart Review of Patients Undergoing Ketamine Infusions | Bipolar disorder Ketamine | 0.5-0.75 mg/kg | IV | range per clinic protocol Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol. Dose data found during issue #220 source review. | Source Backed paper-text | paper:real-world-effectiveness-of-repeated-ketamine-infusions-borderline treatment prior to the emergence of COVID-19 in Ontario, Canada. === METHODS === We performed a retrospective case series analysis of adults receiving four IV ketamine infusions (0.5-0.75 mg/kg) over ~2 weeks for TRD in an outpatient clinic in Ontario, Canada to evaluate treatment response during COVID-19. Treatment outcomes were compared between adults who received trea |
Chart Review of Patients Undergoing Ketamine Infusions | MDD Ketamine | 0.5-0.75 mg/kg | IV | range per clinic protocol Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol. Dose data found during issue #220 source review. | Source Backed paper-text | paper:real-world-effectiveness-of-repeated-ketamine-infusions-borderline treatment prior to the emergence of COVID-19 in Ontario, Canada. === METHODS === We performed a retrospective case series analysis of adults receiving four IV ketamine infusions (0.5-0.75 mg/kg) over ~2 weeks for TRD in an outpatient clinic in Ontario, Canada to evaluate treatment response during COVID-19. Treatment outcomes were compared between adults who received trea |
Chart Review of Patients Undergoing Ketamine Infusions | OCD Ketamine | 0.5-0.75 mg/kg | IV | range per clinic protocol Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol. Dose data found during issue #220 source review. | Source Backed paper-text | paper:real-world-effectiveness-of-repeated-ketamine-infusions-borderline treatment prior to the emergence of COVID-19 in Ontario, Canada. === METHODS === We performed a retrospective case series analysis of adults receiving four IV ketamine infusions (0.5-0.75 mg/kg) over ~2 weeks for TRD in an outpatient clinic in Ontario, Canada to evaluate treatment response during COVID-19. Treatment outcomes were compared between adults who received trea |
Chart Review of Patients Undergoing Ketamine Infusions | PTSD Ketamine | 0.5-0.75 mg/kg | IV | range per clinic protocol Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol. Dose data found during issue #220 source review. | Source Backed paper-text | paper:real-world-effectiveness-of-repeated-ketamine-infusions-borderline treatment prior to the emergence of COVID-19 in Ontario, Canada. === METHODS === We performed a retrospective case series analysis of adults receiving four IV ketamine infusions (0.5-0.75 mg/kg) over ~2 weeks for TRD in an outpatient clinic in Ontario, Canada to evaluate treatment response during COVID-19. Treatment outcomes were compared between adults who received trea |
Continuation Ketamine in Major Depression | Ketamine + Lithium Ketamine | 0.5 mg/kg | IV repeated over 1 week IV ketamine infusions | Not reviewed existing-data | rapid-and-longer-term-antidepressant-effects-of-repeated-ketamine-infusions-in-t |
Continuation Ketamine in Major Depression | Ketamine + Placebo Ketamine | 0.5 mg/kg | IV repeated over 1 week IV ketamine infusions | Not reviewed existing-data | rapid-and-longer-term-antidepressant-effects-of-repeated-ketamine-infusions-in-t |
Dose-Related Effects of Single IV Ketamine Infusion in Treatment-Resistant Depression: A Randomised Parallel-Group Trial (Su 2017, Taipei Veterans General Hospital) | 0.2mg/kg Ketamine Ketamine | 0.2 mg/kg | IV | fixed single dose | 1 dose R/S-ketamine hydrochloride | Not reviewed existing-data | dose-related-effects-of-adjunctive-ketamine-in-taiwanese-patients-with-treatment |
Dose-Related Effects of Single IV Ketamine Infusion in Treatment-Resistant Depression: A Randomised Parallel-Group Trial (Su 2017, Taipei Veterans General Hospital) | 0.5mg/kg Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose R/S-ketamine hydrochloride | Not reviewed existing-data | dose-related-effects-of-adjunctive-ketamine-in-taiwanese-patients-with-treatment |
Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD) | Ketamine + Naltrexone/placebo Ketamine | 0.5 mg/kg | IV single dose | 2 doses Ketamine 0.5 mg/kg IV infusion; two sessions separated by ~30 days. | Not reviewed existing-data | attenuation-of-antidepressant-and-antisuicidal-effects-of-ketamine-by-opioid-rec |
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | Ketamine 0.1 mg/kg Ketamine | 0.1 mg/kg | IV single infusion | 1 dose | Not reviewed existing-data | efficacy-of-intravenous-ketamine-treatment-in-anxious-versus-nonanxious-unipolar |
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | Ketamine 0.2 mg/kg Ketamine | 0.2 mg/kg | IV single infusion | 1 dose | Not reviewed existing-data | efficacy-of-intravenous-ketamine-treatment-in-anxious-versus-nonanxious-unipolar |
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | Ketamine 0.5 mg/kg Ketamine | 0.5 mg/kg | IV single infusion | 1 dose | Not reviewed existing-data | efficacy-of-intravenous-ketamine-treatment-in-anxious-versus-nonanxious-unipolar |
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | Ketamine 1.0 mg/kg Ketamine | 1 mg/kg | IV single infusion | 1 dose | Not reviewed existing-data | efficacy-of-intravenous-ketamine-treatment-in-anxious-versus-nonanxious-unipolar |
Effectiveness of ketamine therapy among patients with treatment-resistant depression: a double-blind, randomised, controlled trial | Fixed-dose ketamine 0.5 mg/kg Ketamine | 0.5 mg/kg | Other | multi-dose twice weekly for 4 weeks | 8 doses Subcutaneous injection. | Not reviewed existing-data | efficacy-and-safety-of-a-4-week-course-of-repeated-subcutaneous-ketamine-injecti |
Effectiveness of ketamine therapy among patients with treatment-resistant depression: a double-blind, randomised, controlled trial | Flexible-dose ketamine 0.5-0.9 mg/kg Ketamine | 0.5-0.9 mg/kg | Other | titrated twice weekly for 4 weeks | 8 doses Subcutaneous injection; escalation steps 0.6, 0.75, and 0.9 mg/kg if not improved by 50%. | Not reviewed existing-data | efficacy-and-safety-of-a-4-week-course-of-repeated-subcutaneous-ketamine-injecti |
Effectiveness of ketamine therapy among patients with treatment-resistant depression: a double-blind, randomised, controlled trial | Ketamine (combined KADS cohorts) Ketamine | 0.5-0.9 mg/kg | Other | titrated twice weekly for 4 weeks | 8 doses Subcutaneous racemic ketamine; fixed-dose cohort used 0.5 mg/kg and flexible-dose cohort escalated 0.5-0.9 mg/kg. | Not reviewed existing-data | efficacy-and-safety-of-a-4-week-course-of-repeated-subcutaneous-ketamine-injecti |
Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy | Ketamine Ketamine | 0.2-0.5 mg/kg | IV per ECT session | 12 doses Administered with usual propofol induction (0.75–1 mg/kg) | Not reviewed existing-data | low-dose-ketamine-does-not-improve-the-speed-of-recovery-from-depression-in-elec |
Effects of single intravenous arketamine dose as an adjunctive therapy for treatment-resistant unipolar depression: a randomized, double-blind, crossover, placebo-controlled trial | Arketamine Ketamine | 0.5 mg/kg | IV | fixed single dose per crossover period | 1 dose Pure (R)-ketamine hydrochloride, enantiomeric excess >99.0%; each participant received arketamine in one of two crossover periods. | Not reviewed existing-data | arketamine-as-adjunctive-therapy-for-treatment-resistant-depression-a-placebo-co |
Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression | Single ketamine + midazolam Ketamine | 0.5 mg/kg | IV single infusion | 1 dose Single ketamine infusion administered on final infusion day; infusion over 40 minutes. | Not reviewed existing-data | a-randomized-double-blind-active-placebo-controlled-study-of-efficacy-safety-and |
Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression | Six ketamine infusions Ketamine | 0.5 mg/kg | IV six infusions over 12 days | 6 doses Infusions on days 1,3,5,8,10,12; each infusion over 40 minutes. | Not reviewed existing-data | a-randomized-double-blind-active-placebo-controlled-study-of-efficacy-safety-and |
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) | Ketamine infusion Ketamine | 0.5 mg/kg | IV twice weekly | 6 doses 0.5 mg/kg infusion over 40 minutes; dose may be modified if clinically warranted. | Not reviewed existing-data | ketamine-versus-ect-for-nonpsychotic-treatment-resistant-major-depression |
Emergency Ketamine Treatment of Suicidal Ideation | Intranasal Ketamine Ketamine | 0.2 mg/kg | Other two doses | 2 doses Intranasal administration by physician | Not reviewed existing-data | single-fixed-dose-intranasal-ketamine-for-alleviation-of-acute-suicidal-ideation |
Examining the Impact of Sirolimus on Ketamine’s Antidepressant Effects | Ketamine + Placebo Ketamine | 0.5 mg/kg | IV two sessions | 2 doses Infusion over ~40 minutes. | Not reviewed existing-data | modulation-of-the-antidepressant-effects-of-ketamine-by-the-mtorc1-inhibitor-rap |
Examining the Impact of Sirolimus on Ketamine’s Antidepressant Effects | Ketamine + Sirolimus Ketamine | 0.5 mg/kg | IV two sessions | 2 doses Infusion over ~40 minutes; one infusion paired with sirolimus, the other with placebo. | Not reviewed existing-data | modulation-of-the-antidepressant-effects-of-ketamine-by-the-mtorc1-inhibitor-rap |
High-Dose IV Ketamine Infusion for Combat-Related PTSD in Veterans: Prospective Observational Case Series (Ross 2019, Ann Clin Psychiatry) | Ketamine infusion Ketamine | 1.94 mg/kg | IV | titrated six 1-hour infusions over a 2-to 3-week period | 6 doses First infusion began at 1 mg/kg (max 60 mg); subsequent doses were adjusted based on patient response to achieve PTR. Mean dose was 1.94 mg/kg. | Not reviewed existing-data | high-dose-ketamine-infusion-for-the-treatment-of-posttraumatic-stress-disorder-i |
IM Ketamine vs Oral Ketamine vs ECT in Major Depressive Disorder with Suicidal Ideation: A Randomised Pilot Study (Kheirabadi 2020, Isfahan) | IM Ketamine Ketamine | 0.5 mg/kg | IM | multi-dose 6 to 9 injections during 3 weeks (with a 2- to 3-day interval) | 9 doses Racemic ketamine (R-ketamine) administered in gluteus medius site. | Not reviewed existing-data | comparison-of-rapid-antidepressant-and-antisuicidal-effects-of-intramuscular-ket |
IM Ketamine vs Oral Ketamine vs ECT in Major Depressive Disorder with Suicidal Ideation: A Randomised Pilot Study (Kheirabadi 2020, Isfahan) | Oral Ketamine Ketamine | 1 mg/kg | Oral | multi-dose every 2 to 3 days up to 6 to 9 sessions during 3 weeks | 9 doses R-ketamine administered with flavors and sweeteners to eliminate bitter taste. | Not reviewed existing-data | comparison-of-rapid-antidepressant-and-antisuicidal-effects-of-intramuscular-ket |
Intranasal Ketamine vs Midazolam for TRD: Double-Blind Parallel Pilot RCT (Gálvez 2018, Thompson Institute / Otago) | Ketamine Ketamine | 100 mg | Intranasal | multi-dose three times a week for 2 weeks, then weekly for 2 weeks | 8 doses Each treatment consisted of 10 separate IN sprays, self-administered 5 min apart (later modified to 5 min intervals between sprays due to tolerability). | Not reviewed existing-data | repeated-intranasal-ketamine-for-treatment-resistant-depression-the-way-to-go-re |
Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery | Ketamine (double blind) Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose Infusion over 40 minutes (0.5 mg/kg). | Not reviewed existing-data | trial-of-ketamine-masked-by-surgical-anesthesia-in-depressed-patients |
Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery | Ketamine (open label) Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose Infusion over 40 minutes (0.5 mg/kg). | Not reviewed existing-data | trial-of-ketamine-masked-by-surgical-anesthesia-in-depressed-patients |
Intravenous Arketamine for Treatment-Resistant Depression: Open-Label Pilot Study (UMIN000038347, Federal University of Bahia, Brazil) | Arketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose delivered over 40 min | Not reviewed existing-data | intravenous-arketamine-for-treatment-resistant-depression-open-label-pilot-study |
Intravenous Ketamine Plus Neurocognitive Training for Depression | Ketamine + Cognitive Training Ketamine | 0.5 mg/kg | IV single infusion | 1 dose Subanesthetic intravenous ketamine infusion over 40 minutes. | Not reviewed existing-data | a-novel-brief-fully-automated-intervention-to-extend-the-antidepressant-effect-o |
Intravenous Ketamine Plus Neurocognitive Training for Depression | Ketamine + Sham Training Ketamine | 0.5 mg/kg | IV single infusion | 1 dose Subanesthetic intravenous ketamine infusion over 40 minutes. | Not reviewed existing-data | a-novel-brief-fully-automated-intervention-to-extend-the-antidepressant-effect-o |
IV Ketamine + Propofol-ECT for Treatment-Resistant Depression: Pilot fMRI Study (Zhang 2020, Tianjin Anding Hospital) | Ketamine plus propofol-ECT Ketamine | 0.5 mg/kg | IV | multi-dose six times within 14 days | 6 doses Injected at 10:00 pm the day before propofol-ECT | Not reviewed existing-data | ketamine-plus-propofol-electroconvulsive-therapy-ect-transiently-improves-the-an |
IV Ketamine for Adolescents with Treatment-Resistant Depression: Open-Label Pilot (Cullen 2018, University of Minnesota) | Ketamine Ketamine | 0.5 mg/kg | IV | multi-dose six infusions over 2 weeks | 6 doses Initial dosing for first 5 participants was based on ideal body weight, then switched to actual body weight for subsequent participants. | Not reviewed existing-data | intravenous-ketamine-for-adolescents-with-treatment-resistant-depression-an-open |
IV Ketamine Series for MDD/PTSD: Epigenetic Clock and DNA Methylation Study (Wild Health 2024, Lexington KY) | Ketamine infusion series Ketamine | 0.5 mg/kg | IV | multi-dose six infusions over 2-3 weeks | 6 doses Subanesthetic dose | Not reviewed existing-data | ketamine-treatment-effects-on-dna-methylation-and-epigenetic-biomarkers-of-aging |
KET01 Oral Prolonged-Release Ketamine for TRD: 3-Arm RCT (Colla 2024, 3 Swiss Hospitals) | KET01 160mg Ketamine | 160 mg | Oral | multi-dose twice daily | 14 doses Prolonged-release formulation (KET01); administered as 80 mg twice a day. | Not reviewed existing-data | oral-prolonged-release-ketamine-in-treatment-resistant-depression-a-double-blind |
KET01 Oral Prolonged-Release Ketamine for TRD: 3-Arm RCT (Colla 2024, 3 Swiss Hospitals) | KET01 240mg Ketamine | 240 mg | Oral | multi-dose twice daily | 14 doses Prolonged-release formulation (KET01); administered as 120 mg twice a day. | Not reviewed existing-data | oral-prolonged-release-ketamine-in-treatment-resistant-depression-a-double-blind |
Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot | Ketamine-treated sample Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose | Not reviewed existing-data | a-pilot-study-of-ketamine-infusion-after-suicide-attempt-new-frontiers-in-treati |
Ketamine and Global Brain Connectivity in MDD: Open-Label fMRI Study (Abdallah 2017, Yale) | MDD Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose administered via infusion pump over 40 min | Not reviewed existing-data | ketamine-treatment-and-global-brain-connectivity-in-major-depression |
Ketamine and Mindfulness Based Cognitive Therapy (MBCT) in Treatment of Post-Traumatic Stress Disorder (PTSD): Comparison of Treatment Efficacy and Metabolomic Profiles | TIMBER-K Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose (R,S)-ketamine infusion; combined with 12 TIMBER sessions (3 in first week, then weekly) | Not reviewed existing-data | trauma-interventions-using-mindfulness-based-extinction-and-reconsolidation-timb |
Ketamine and Mindfulness Based Cognitive Therapy (MBCT) in Treatment of Post-Traumatic Stress Disorder (PTSD): Comparison of Treatment Efficacy and Metabolomic Profiles | TIMBER-K (Crossover) Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose Crossover arm for patients experiencing sustained relapse | Not reviewed existing-data | trauma-interventions-using-mindfulness-based-extinction-and-reconsolidation-timb |
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD) | Ketamine Ketamine | 0.5 mg/kg | IV single dose | 1 dose Infused over 40 minutes | Not reviewed existing-data | efficacy-of-intravenous-ketamine-for-treatment-of-chronic-posttraumatic-stress-d |
Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD) | Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose administered over 40 min | Not reviewed existing-data | neuroimaging-correlates-and-predictors-of-response-to-repeated-dose-intravenous- |
Ketamine as an Adjunctive Therapy for Major Depression (KARMA-dep) | Ketamine Ketamine | 0.05 mg/kg | IV weekly | 4 doses Four once-weekly infusions; blood sampling at four time-points during first infusion and before final infusion for biomarker studies. | Not reviewed existing-data | ketamine-as-an-adjunctive-therapy-for-major-depression-a-randomised-controlled-p |
Ketamine Autonomic / EEG Biomarkers in MDD: Pooled Czech Controlled Trials 2010–2015 (Meyer / Horacek / Novak, NIMH CZ) | Ketamine Ketamine | 0.54 mg/kg | IV | fixed single dose | 1 dose Loading dose of 0.27 mg/kg for the first 10 min, followed by an infusion of 0.27 mg/kg within 20 min. Total dose 0.54 mg/kg within 30 min. | Not reviewed existing-data | predictive-value-of-heart-rate-in-treatment-of-major-depression-with-ketamine-in |
Ketamine for Depression and Alcohol Dependence | Ketamine Ketamine | 0.5 mg/kg | IV single dose | 1 dose Administered as a 40-minute infusion (Ketalar 0.5 mg/kg). | Not reviewed existing-data | association-of-combined-naltrexone-and-ketamine-with-depressive-symptoms-in-a-ca |
Ketamine for Mood Disorders With Suicidal Ideation | Ketamine Ketamine | 0.5 mg/kg | IV single dose | 1 dose Infused over 40 minutes; dose based on weight. | Not reviewed existing-data | a-feasibility-study-of-low-dose-ketamine-for-acute-management-of-suicidal-ideati |
Ketamine for Older Adults Pilot | Ketamine IV Ketamine | 0.5 mg/kg | IV twice weekly then weekly | 12 doses Infused over 40 minutes; acute: twice weekly for 4 weeks (8); continuation: weekly for 4 weeks (4). | Not reviewed existing-data | intravenous-ketamine-for-late-life-treatment-resistant-depression-a-pilot-study- |
Ketamine for Reduction of Alcoholic Relapse (KARE) | Ketamine+Education Ketamine | 0.8 mg/kg | IV | multi-dose three sessions | 3 doses 0.8 mg/kg IV infusion over 45 minutes per session | Not reviewed existing-data | adjunctive-ketamine-with-relapse-prevention-based-psychological-therapy-in-the-t |
Ketamine for Reduction of Alcoholic Relapse (KARE) | Ketamine+Psychotherapy Ketamine | 0.8 mg/kg | IV | multi-dose three sessions | 3 doses 0.8 mg/kg IV infusion over 45 minutes per session | Not reviewed existing-data | adjunctive-ketamine-with-relapse-prevention-based-psychological-therapy-in-the-t |
Ketamine for Suicidality in Bipolar Depression | Ketamine Ketamine | 0.5 mg/kg | IV single dose | 1 dose Infusion over ~40 minutes | Not reviewed existing-data | ketamine-versus-midazolam-in-bipolar-depression-with-suicidal-thoughts-a-pilot-m |
Ketamine for Treatment Resistant Late-Life Depression | Ketamine 0.10 mg/kg Ketamine | 0.1 mg/kg | IV | fixed single dose | 1 dose 40-minute infusion. | Not reviewed existing-data | identification-of-an-optimal-dose-of-intravenous-ketamine-for-late-life-treatmen |
Ketamine for Treatment Resistant Late-Life Depression | Ketamine 0.25 mg/kg Ketamine | 0.25 mg/kg | IV | fixed single dose | 1 dose 40-minute infusion. | Not reviewed existing-data | identification-of-an-optimal-dose-of-intravenous-ketamine-for-late-life-treatmen |
Ketamine for Treatment Resistant Late-Life Depression | Ketamine 0.50 mg/kg Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose 40-minute infusion. | Not reviewed existing-data | identification-of-an-optimal-dose-of-intravenous-ketamine-for-late-life-treatmen |
Ketamine in the Treatment of Suicidal Depression | Ketamine Ketamine | 0.5 mg/kg | IV single dose IV infusion over ~40 minutes | Not reviewed existing-data | ketamine-for-rapid-reduction-of-suicidal-thoughts-in-major-depression-a-midazola |
Ketamine Infusion for Social Anxiety Disorder | Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose administered over 40 min | Not reviewed existing-data | ketamine-for-social-anxiety-disorder-a-randomized-placebo-controlled-crossover-t |
Ketamine Infusion for Treatment-resistant Major Depressive Disorder | Ketamine IV Ketamine | 0.5 mg/kg | IV twice weekly | 6 doses Infusion over 45 minutes; non-responders may escalate to 0.75 mg/kg after 3 infusions. | Not reviewed existing-data | repeat-dose-ketamine-augmentation-for-treatment-resistant-depression-with-chroni |
Ketamine Infusions for PTSD and Treatment-Resistant Depression | Six ketamine infusions Ketamine | 0.5 mg/kg | IV six infusions over 2 weeks | 6 doses Infusions on Mon/Wed/Fri; 3 h observation post-infusion. | Not reviewed existing-data | efficacy-safety-and-durability-of-repeated-ketamine-infusions-for-comorbid-postt |
Ketamine Modulation of Reward Processing fMRI in Remitted Unmedicated MDD: Double-Blind Crossover (Kotoula 2022) | Ketamine 0.5mg/kg Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose 40min steady state infusion | Not reviewed existing-data | ketamine-modulates-the-neural-correlates-of-reward-processing-in-unmedicated-pat |
Ketamine Plus Lithium in Treatment-Resistant Depression | Ketamine + Lithium Ketamine | Not reported | IV multiple infusions Repeated ketamine infusions over 1 week per protocol. | Not reviewed altered-peripheral-immune-profiles-in-treatment-resistant-depression-response-to |
Ketamine Plus Lithium in Treatment-Resistant Depression | Ketamine + Placebo Ketamine | Not reported | IV multiple infusions Repeated ketamine infusions over 1 week per protocol. | Not reviewed altered-peripheral-immune-profiles-in-treatment-resistant-depression-response-to |
Ketamine Psychoactive Effects in Cocaine Dependence: Double-Blind 3-Way Crossover Pilot (Dakwar / Nunes, NYSPI Columbia 2014) | Ketamine 0.41mg/kg Ketamine | 0.41 mg/kg | IV | fixed single dose | 1 dose 52-min infusion (2-min bolus followed by 50 min infusion) | Not reviewed existing-data | therapeutic-infusions-of-ketamine-do-the-psychoactive-effects-matter |
Ketamine Psychoactive Effects in Cocaine Dependence: Double-Blind 3-Way Crossover Pilot (Dakwar / Nunes, NYSPI Columbia 2014) | Ketamine 0.71mg/kg Ketamine | 0.71 mg/kg | IV | fixed single dose | 1 dose 52-min infusion (2-min bolus followed by 50 min infusion) | Not reviewed existing-data | therapeutic-infusions-of-ketamine-do-the-psychoactive-effects-matter |
Ketamine Therapy For Internalizing Disorders: Is There A Single Mechanism? | Ketamine 0.5 mg/kg IM Ketamine | 0.5 mg/kg | IM single dose in one crossover period | 1 dose Adjunct/co-administered substances noted in arm: Ondansetron 4 mg Oral antiemetic. | Not reviewed existing-data | ketamine-for-treatment-resistant-obsessive-compulsive-disorder-double-blind-acti |
Ketamine Therapy For Internalizing Disorders: Is There A Single Mechanism? | Ketamine 1.0 mg/kg IM Ketamine | 1 mg/kg | IM single dose in one crossover period | 1 dose Adjunct/co-administered substances noted in arm: Ondansetron 4 mg Oral antiemetic. | Not reviewed existing-data | ketamine-for-treatment-resistant-obsessive-compulsive-disorder-double-blind-acti |
Ketamine-Assisted Psychotherapy for Chronic Pain and Comorbid Depression: Pilot Study (Batievsky 2023, Front Pain Res) | Psychedelic approach Ketamine | 70 mg | IM | multi-dose twice weekly | 12 doses Dosages ranged from 40 to 100 mg. Regimen: session 1 (40 & 50mg), session 2 (50 & 60mg), session 3 (60 & 70mg), session 4 (70 & 80mg), session 5 (80 & 90mg), session 6 (90 & 100mg). 6 sessions over 6 weeks. | Not reviewed existing-data | ketamine-assisted-psychotherapy-treatment-of-chronic-pain-and-comorbid-depressio |
Ketamine-Assisted Psychotherapy for Chronic Pain and Comorbid Depression: Pilot Study (Batievsky 2023, Front Pain Res) | Psycholytic approach Ketamine | 50 mg | Sublingual | multi-dose weekly | 6 doses Dosages ranged from 25 to 75 mg. Regimen: sessions 1 & 2 (25mg), sessions 3 & 4 (50mg), sessions 5 & 6 (75mg). 6 sessions over 6 weeks. Lozenges held/swished for 15 min. | Not reviewed existing-data | ketamine-assisted-psychotherapy-treatment-of-chronic-pain-and-comorbid-depressio |
Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): open-label pilot study | Low-dose oral ketamine Ketamine | Needs review | Oral | titrated once weekly for six weeks | 6 doses Paper describes low-dose oral ketamine in a titrating-up manner; exact dose schedule is in the primary OKTOP report, not this biomarker paper. Supplement is not parsed as PDF: paper:blood-biomarker-changes-and-relationships-after-low-dose-oral-ketamine-treatment-for-post / Supplementary Material 1 | Supplement is not parsed as PDF: paper:blood-biomarker-changes-and-relationship... | Needs Review needs-review | blood-biomarker-changes-and-relationships-after-low-dose-oral-ketamine-treatment-for-post |
Low-Dose Ketamine Effects on PFC and Amygdala in TRD: Double-Blind 3-Arm RCT with FDG-PET (Li CT / Su TP, TVGH Taiwan; UMIN000016985) | Ketamine 0.2mg/kg Ketamine | 0.2 mg/kg | IV | fixed single dose | 1 dose 40-min constant intravenous infusion | Not reviewed existing-data | the-effects-of-low-dose-ketamine-on-the-prefrontal-cortex-and-amygdala-in-treatm |
Low-Dose Ketamine Effects on PFC and Amygdala in TRD: Double-Blind 3-Arm RCT with FDG-PET (Li CT / Su TP, TVGH Taiwan; UMIN000016985) | Ketamine 0.5mg/kg Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose 40-min constant intravenous infusion | Not reviewed existing-data | the-effects-of-low-dose-ketamine-on-the-prefrontal-cortex-and-amygdala-in-treatm |
Multiple IV Ketamine Infusions for Major Depressive Disorder: Open-Label Study (Zheng 2019, Guangzhou Brain Hospital) | Six ketamine infusions Ketamine | 0.5 mg/kg | IV | multi-dose three times weekly | 6 doses Infusions administered over 40 minutes; administered over a course of 12 days. | Not reviewed existing-data | investigation-of-medical-effect-of-multiple-ketamine-infusions-on-patients-with- |
Multiple vs Single Ketamine-Assisted Psychotherapy (KPT) for Heroin Dependence: Evaluator-Blind RCT (Krupitsky, St Petersburg Russia 2007) | Multiple KPT group Ketamine | 2 mg/kg | IM | multi-dose three sessions at monthly intervals | 3 doses Sessions were 1.5 to 2 hours long; accompanied by psychotherapy. | Not reviewed existing-data | single-versus-repeated-sessions-of-ketamine-assisted-psychotherapy-for-people-wi |
Multiple vs Single Ketamine-Assisted Psychotherapy (KPT) for Heroin Dependence: Evaluator-Blind RCT (Krupitsky, St Petersburg Russia 2007) | Single KPT group Ketamine | 2 mg/kg | IM | fixed single dose | 1 dose Session was 1.5 to 2 hours long; accompanied by psychotherapy. | Not reviewed existing-data | single-versus-repeated-sessions-of-ketamine-assisted-psychotherapy-for-people-wi |
Open-Label IV Ketamine Series for MDD/Bipolar Depression with Pain Mediation Analysis (Wu 2023, China) | Ketamine Ketamine | 0.5 mg/kg | IV | multi-dose repeated infusions | 6 doses Administered via intravenous pump with 0.9% sodium chloride injection over 40 min; infusions occurred Monday, Wednesday, and Friday over a two-week period. | Not reviewed existing-data | pain-mediates-the-improvement-of-social-functions-of-repeated-intravenous-ketami |
Opiate Suicide Study in Patients With Major Depression | Ketamine + Buprenorphine Ketamine | 0.5 mg/kg | IV single dose | 1 dose Infusion over 40 minutes | Not reviewed existing-data | low-dose-buprenorphine-following-ketamine-treatment-for-suicidal-ideation-in-major-depressive |
Opiate Suicide Study in Patients With Major Depression | Ketamine + Placebo Ketamine | 0.5 mg/kg | IV single dose | 1 dose Infusion over 40 minutes | Not reviewed existing-data | low-dose-buprenorphine-following-ketamine-treatment-for-suicidal-ideation-in-major-depressive |
Optimization of IV Ketamine for Treatment Resistant Depression | Ketamine Ketamine | 0.5 mg/kg | IV single dose | 1 dose Infused over 40 minutes | Not reviewed existing-data | antidepressant-efficacy-of-ketamine-in-treatment-resistant-major-depression-a-tw |
Oral Ketamine vs Diclofenac for Mild-to-Moderate Depression in Chronic Headache Patients: A Double-Blind RCT (IRCT201508201556N80, Imam Hospital Tehran) | Ketamine Ketamine | 50 mg | Oral | multi-dose three times daily | 126 doses Fixed daily dosage of 150 mg | Not reviewed existing-data | efficacy-and-safety-of-oral-ketamine-versus-diclofenac-to-alleviate-mild-to-mode |
PET Imaging of mGLuR5 With Drug Challenge | Ketamine Ketamine | Not reported | IV single dose Administered prior to one PET scan to induce glutamate release | Not reviewed acute-cognitive-effects-of-single-dose-intravenous-ketamine-in-major-depressive- |
Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression (PEAK) | Ketamine 0.5 mg/kg (under propofol sedation) Ketamine | 0.5 mg/kg | IV | fixed single dose over 40 minutes | 1 dose Adjunct/co-administered substances noted in arm: Propofol IV anxiolytic. | Not reviewed existing-data | protocol-and-pilot-results-for-a-double-blind-randomized-placebo-controlled-trial-of-ketamine |
Racemic Ketamine vs S(+)-Esketamine for TRD: Bicentric Double-Blind RCT (UFBA Brazil, UMIN000032355) | Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose Infusion duration of 40 min | Not reviewed existing-data | neurocognitive-aspects-of-ketamine-and-esketamine-on-subjects-with-treatment-res |
Rapid Antidepressant Effects of Ketamine in Major Depression | Ketamine→Placebo Ketamine | 0.5 mg/kg | IV single dose | 1 dose 40-minute infusion | Not reviewed existing-data | replication-of-ketamines-antidepressant-efficacy-in-bipolar-depression-a-randomi |
Rapid Antidepressant Effects of Ketamine in Major Depression | Placebo→Ketamine Ketamine | 0.5 mg/kg | IV single dose | 1 dose 40-minute infusion | Not reviewed existing-data | replication-of-ketamines-antidepressant-efficacy-in-bipolar-depression-a-randomi |
Single Bolus Low-Dose Ketamine for Prevention of Postpartum Depression After Caesarean Section: A Randomized, Double-Blind, Placebo-Controlled Trial | Ketamine Ketamine | 0.25 mg/kg | IV | fixed single dose | 1 dose diluted to 10 mL with 0.9% saline | Not reviewed existing-data | single-bolus-low-dose-of-ketamine-does-not-prevent-postpartum-depression-a-rando |
Single IV Ketamine for Bipolar Depression: Open Neurocognitive Pilot Study (Permoda-Osip / Rybakowski, Poznan Poland) | Ketamine infusion Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose Performed between 8:00-8:45 h | Not reviewed existing-data | single-ketamine-infusion-and-neurocognitive-performance-in-bipolar-depression |
Single IV Ketamine vs Midazolam for TRD with Suicidal Ideation: dPFC Volumetric RCT (Li WC / Su TP / Li CT, TVGH Taiwan) | Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose Low-dose ketamine infusion | Not reviewed existing-data | right-dorsolateral-prefrontal-cortex-volumetric-reduction-is-associated-with-ant |
Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation (KSI) | Ketamine Ketamine | 0.5 mg/kg | IV single dose | 1 dose 1 mg/mL solution; 50 mg maximum; infusion over 40 minutes. | Not reviewed existing-data | single-dose-iv-ketamine-for-adolescent-suicidal-ideation-in-the-emergency-department-a-pilot |
Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care | Ketamine Ketamine | 50-150 mg | Other | multi-dose three sessions | 3 doses Intranasal: Day 1 50 mg; Day 4 50–100 mg; Day 7 50–150 mg. | Not reviewed existing-data | a-phase-ii-open-label-clinical-trial-of-intranasal-ketamine-for-depression-in-pa |
Sub-Anaesthetic Ketamine at C-Section to Prevent Postpartum Depression: Double-Blind RCT (Alipoor / Sarkoohi, Rafsanjan Iran 2021) | Ketamine-Nesdonal group Ketamine | 0.5 mg/kg | IV | fixed single dose during anesthesia induction | 1 dose Sub-anesthetic ketamine dose administered with Nesdonal during induction of general anesthesia. Adjunct/co-administered substances noted in arm: Nesdonal (thiopental sodium) 1-2 mg/kg IV general anesthesia induction. | Not reviewed existing-data | the-effect-of-ketamine-on-preventing-postpartum-depression |
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. | Ketamine Ketamine | 0.5 mg/kg | IV three sessions | 3 doses Each infusion given over 100 minutes; blood samples before and after dosing for biomarker development. | Not reviewed existing-data | patients-recovery-and-non-recovery-narratives-after-intravenous-ketamine-for-tre |
The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence | Ketamine Ketamine | 0.5 mg/kg | IV | fixed single dose | 1 dose 40-minute slow-drip infusion; combined with MBRP | Not reviewed existing-data | a-single-ketamine-infusion-combined-with-mindfulness-based-behavioral-modificati |
The Effect of Glutamatergic Modulation on Cocaine Self-administration | Ketamine Ketamine | 0.71 mg/kg | IV | fixed single dose | 1 dose administered as 0.11 mg/kg 2-min bolus followed by 0.60 mg/kg in saline over 50 min | Not reviewed existing-data | cocaine-self-administration-disrupted-by-the-n-methyl-d-aspartate-receptor-antag |
Three-Arm Double-Blind RCT of Ketamine Dose in ECT Anaesthesia for TRD (Zhong 2016, China) | Ketamine Ketamine | 0.8 mg/kg | IV | multi-dose Each ECT session, three times per week | 8 doses Administered as anesthesia for the eight ECT treatments. | Not reviewed existing-data | mood-and-neuropsychological-effects-of-different-doses-of-ketamine-in-electrocon |
Three-Arm Double-Blind RCT of Ketamine Dose in ECT Anaesthesia for TRD (Zhong 2016, China) | Ketamine + Propofol Ketamine | 0.5 mg/kg | IV | multi-dose Each ECT session, three times per week | 8 doses Subanesthetic ketamine dose administered as part of anesthesia for the eight ECT treatments. | Not reviewed existing-data | mood-and-neuropsychological-effects-of-different-doses-of-ketamine-in-electrocon |
Treatment Resistant Depression (Pilot) | 100-hour ketamine Ketamine | 0.002 mg/kg/min | IV single infusion 100-hour continuous infusion (reported rate 0.00225 mg/kg/min). | Not reviewed existing-data | prolonged-ketamine-infusion-modulates-limbic-connectivity-and-induces-sustained- |
Treatment Resistant Depression (Pilot) | 40-minute ketamine Ketamine | Not reported | IV single infusion Standard 40-minute IV ketamine infusion (per protocol). | Not reviewed prolonged-ketamine-infusion-modulates-limbic-connectivity-and-induces-sustained- |